INS and type 2 diabetes mellitus: Finally, the COMBINE 3 trial (NCT05013229) compared once-weekly IcoSema with conventional basal-bolus therapy (glargine + insulin aspart) in 679 patients with type 2 diabetes insufficiently controlled on basal insulin (6).